Business
Bicara is a clinical-stage biopharmaceutical company developing bifunctional therapies for solid tumors, led by ficerafusp alfa.
Bicara remained pre-revenue as losses and cash burn worsened, while RA Capital bought shares amid heavy sales.
The read at a glance✓ Audited against SEC data
- Business mix — Bifunctional solid-tumor therapyNote
- Revenue — No revenue reportedNote
- Losses — Net loss more than doubledWatch
- Cash — Free cash flow fell to -$107.1MWatch
- Balance sheet — Equity fell 18.4%Watch
- Insiders — 1 purchase / 44 salesNote
- Accounting — Altman-Z, Beneish-M, and earnings-quality unavailableNote
Leadership changes
From Bicara Therapeutics Inc.'s own filings, the day they're filed.
- Kiran Mazumdar-Shaw · Directors · departureeff. 2026-07-28
- Christy Oliger · director · departureeff. 2026-07-28
- D. Jeremy Bender · departureeff. 2026-07-26
Latest filings
- 8-K · Company announcement2026-08-25
- 10-Q · Quarterly report2026-08-11
- 8-K · Company announcement2026-08-11
- 8-K · Company announcement2026-07-28
- 8-K · Company announcement2026-06-10
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Bicara Therapeutics Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.